Startup Member Companies
AHP HEALTH INNOVATION: Improving quality of life through thoughtful partnerships between humans and microbes.
AXIO BIOPHARMA: Accelerating life-saving medicines to the clinic with AI-powered biologic solutions
Axio BioPharma is an emerging contract development and manufacturing organization (CDMO) specializing in recombinant proteins, with an initial focus on monoclonal antibodies (mAbs). We leverage our proprietary AI model to accurately predict robust and scalable manufacturing processes directly from electronic protein sequences. By integrating AI into our development strategies, Axio BioPharma aims to significantly reduce traditional process development timelines and accelerate the journey from concept to clinic. As we move forward, our goal is to transform the landscape of biopharmaceutical manufacturing, making treatments available more quickly.
AYRFLO: A non-invasive and wearable device to monitor respiratory changes in patients under sedation.
AyrFlo, Inc. is a medical device startup company that has developed a novel respiratory monitoring method to detect respiratory compromise in patients undergoing sedation during medical procedures. It employs ultrasound signaling along with a machine learning algorithm for the early detection of airway compromise, airway failure, and/or obstruction with dynamic and quantitative feedback of changes of airflow and other parameters of respiration. With this device, AyrFlo aims to lower the currently high morbidity and mortality rates in patients under sedation.
CELLULAR LOGISTICS: Unique combined therapeutic approaches for the treatment of heart failure.
Cellular Logistics, Inc. is dedicated to improving the lives of individuals suffering from heart failure. CL was founded in 2016 by a multi-disciplinary clinical and scientific team from the University of Wisconsin-Madison School of Medicine and Public Health. Our company vision is to help create a world where a new generation of therapies can reverse the debilitating symptoms of heart failure; dramatically reducing re-hospitalization and enabling patients to live longer, healthier lives. Our product, Tandem™ HF, holds the promise of revitalizing a damaged heart and creating unique combined therapeutic approaches for the world’s leading cause of death.
CHILD HEALTH IMPRINTS: Saving children’s lives, the data way.
Child Health Imprints (CHIL) USA Inc is engaged in the development and application of IoT, artificial intelligence, and predictive analytics to make an early diagnosis of critical diseases and improve the quality of healthcare provided to neonates. The solution comprises NEO device which collects live physiological data from connected medical devices and live video from the camera. The iNICU plugin captures the clinical data & laboratory data from EMR. The intelligence layer analyses the data and enhance the overall quality of healthcare provided to neonates in NICUs. CHIL solution is currently operational within NICUs in India, Singapore, and South Korea. It is now working with hospitals in Canada and US to expand the solution in North America.
ENDSULIN: A novel gene therapy to cure Diabetes.
Endsulin is reshaping the way we approach a cure for diabetes, focusing on freeing patients from the daily burdens of today’s limited treatments. We are developing a gene therapy to cure type 1 diabetes for the 30 million people worldwide who need it. Please visit www.endsulin.com for more information.
ETERNAL, INC.: Characterization on Exosomes from Bovine ES-Cell Lines
EZRABIO, INC.: Quantifying Gene Expression at the Translational Level.
EzraBio, INC aims to deliver rapid, robust, cost-effective and reliable tools that facilitate the discovery of mRNA translational targets in human diseases. An early-stage biotech startup from Cornell University, EzraBio uses patented cDNA library construction technology to unlock the door of the mRNA translation landscape, and assists researchers in discovering novel targets at the mRNA translational level.
FLUX XII:
Flux XII is building grid batteries to expand the stability and flexibility of utility-scale renewables. This has signficant economic, reliability, and emission impacts. Instead of relying on limited metal chemistries, we’ve developed organic salts with targeted flow battery properties and record performance. This breakthrough comes without sacrificing cost and scalability as these materials can be produced from abundant feedstocks and eventually from a circular carbon economy.
JACE BIOMEDICAL INC: Alleviates the burden caused by proteotoxic diseases.
Jace Biomedical (JBI) is focused on debilitating diseases caused by the aggregation of proteins in the secretory pathway. Through precisely increasing protein degradation only in the endoplasmic reticulum, their approach avoids side-effects that would result from upregulating protein breakdown in the whole cell.
OBVIA PHARMACEUTICALS LTD: Developing the world’s best reactive-oxygen-species scavenger.
A pharmaceutical company created to develop the PrC-210 drug product, which prevents damage to organs from oxidative stress and ischemic reperfusion injury. PrC-210 use is applicable in medical indications such as organ transplantation, radiation protection, myocardial infarction, stroke, sepsis and protection from cytokine storm. The company is focusing on those medical indications where the product can be brought to markets with highest probability of success and is looking for global product approval.
PATHOGENUITY: Expert consulting to boost defenses against viruses
Visit our website: https://www.pathogenuity.bio/
POLYMER FORGE: Accelerating progress in healthcare, biological research, and nanotechnology
A biotechnology company leveraging the potential of bioelectronics to provide innovative tools and solutions for the most challenging healthcare and environmental problems. Polymer Forge's adaptable platform can be used to screen biopolymers and biomimetic libraries for desirable properties, develop biosensors and point-of-care diagnostics, and advance research into neuroprostheses and other interfaces between biological and microelectronic systems.
SQUIRE BIOSCIENCES: Helping companies to deliver on the promise of gene therapy.
Squire Biosciences is developing a simple, scalable approach to manufacture gene therapies.
SYNPHA BIOSCIENCES: Building the next generation of synthetic phage therapeutics
Synpha Biosciences is creating a new generation of synthetic phage therapeutics to treat a wide variety of bacterial diseases. Using patent-protected technology and a novel machine learning AI platform, we build advanced therapeutics that overcome traditional hurdles in phage therapy.
VAXTHERA: A company made of science, joy, and humanity to share with the world.
A Colombian biotechnology company that develops products and services that contributes to Colombia and the region’s health sovereignty, positively impacting people’s health through prevention. Their Madison, WI based location is dedicated to the research and development of biologics.
VGSK TECHNOLOGIES, INC.
VGSK Technologies, Inc., the parent company of ProLung, has created a method for controlled release system for the lungs which can deliver medications into the bloodstream.
WISPERBIO, INC: Improving Lives with Biopharmaceuticals
WisperBio, Inc. is focused on novel biopharmaceutical development.
Graduated Startup Companies
BRAINXELL: Making brains well.
BrainXell provides a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery. From motor neurons to cortical sub-types, they can provide specific models for both disease or normal drug screening.
ACQUIRED BY AMAZON
BLUDIAGNOSTICS: Accurate hormone testing at home - without needles.
BluDiagnostics is bringing break-through technology to the timeless problem of infertility. By providing women and couples with an easy way to monitor key clinical indicators of female fertility, they help people become parents. Bringing together career experts in medical devices, point-of-care testing, data science, and women's health, bluDiagnostics is delivering insights that mandate a new conversation about fertility.
CHLOBIS WATER, INC: Revolutionary electrochemical technologies for desalination and waste water treatment.
ChloBis Water, Inc. is developing an energy-efficient desalination technology that is uniquely positioned to address challenges at the intersection of the water-energy nexus. Our rechargeable desalination cell can achieve membrane-free desalination while simultaneously using salt ions to store and release energy. The technology is based on the patented discovery that bismuth can serve as a practical and efficient chloride-storage electrode, providing unique opportunities to develop novel approaches for both seawater desalination and wastewater treatment.
CIRCULAR INNOVATIONS, LLC: Enabling the Circular Economy with Biotechnology
A synthetic biology company, Circular Innovations, is using the power of life to convert waste streams into chemicals. We do this by rewiring and optimizing the metabolic pathways of industrial yeast to ferment the feedstock into the chemical of interest at high yield, titer, and productivity. Our first project is to convert used-cooking oil into acetone and isopropanol.
COLD WATER TECHNOLOGIES:
Cold Water Technologies is a new is developing an over-the-counter pet nutraceutical for itch relief called Dermigan. The patented product, developed at the University of Wisconsin-Madison, supplements an antibody blood protein in dogs to eliminate the itch.
COMPLETE PHYTOCHEMICAL SOLUTIONS: Providing neutral, unbiased and reliable third-party scientific analyses.
Complete Phytochemical Solutions, LLC provides third-party analytic testing, contract research and consulting services that enable our clients to develop, manufacture and market high quality, efficacious botanical supplements and food products for human and animal nutrition. Third-party testing is a critical component of good manufacturing practices (GMP). Our highest goal is to provide a neutral, unbiased, reliable third-party source of scientific analyses that our clients can depend on.
ACQUIRED BY UPSIDE FOODS
Cultured Decadence: Crustacean-focused cellular aquaculture.
Cultured Decadence is a cellular aquaculture company creating novel methods to make crustacean products using cell culture and tissue engineering techniques.
DIANOMI THERAPEUTICS: Developing next gen therapeutics for inflammatory diseases
A biopharmaceutical company advancing a pipeline of next generation treatments for inflammatory diseases, targeting osteoarthritis and pain. Their proprietary Mineral Coated Microparticle (MCM) technology is designed to provide proven drugs with sustained release delivery for improved stability, safety and efficacy.
EDAN: Providing phenomenal medical devices and healthcare solutions to the world.
A healthcare company dedicated to improving the human condition around the world by delivering value-driven, innovative and high-quality medical products and services.
ELEPHAS BIO: Developing the next generation cancer diagnostic platform.
Elephas is building an instrument platform that will inform how clinicians treat cancer patients. The platform will preserve, analyze and interrogate live human tumors ex vivo. The system is being designed to help determine the best cancer therapy for each patient and has significant potential applications for developing oncology drugs and future cancer research.
EMPIRICO: A next generation therapeutics company
A therapeutics company founded on using medical data sets, human genetics and programmable biology to power novel target discovery and development. Empirico’s Precision Insights Platform was purpose-built for target discovery. With it’s proprietary algorithms, the platform enables Empirico’s scientists to systematically generate, interrogate, and prioritize high-confidence therapeutic hypotheses.
FLAMBEAU RAPIDX: The new frontier of same day mobile lab diagnostics.
Flambeau RapidX’s innovative mobile diagnostic testing system offers unprecedented access and high performance lab results on demand.
GENTUERI: The future of biological sample collection.
Gentueri works with laboratories to improve the quality of results and laboratory efficiency by advancing the collection, preservation and processing of biological samples with innovative devices and kits.
GREGOR DIAGNOSTICS: Better screening for prostate cancer
A molecular diagnostics company developing a revolutionary screening test for prostate cancer, the second deadliest cancer for men. Gregor Diagnostic’s technology can accurately determine if an asymptomatic patient has no cancer, indolent cancer, or aggressive cancer.
IMMUTO SCIENTIFIC: Developer of a technology intended to analyze proteins in the drug development process.
The company's patented technology automates complex protein analysis as part of the drug discovery process for protein therapeutics which is faster than the industry gold standard technique for protein structure analysis, enabling drug developers to determine the protein structure in less than 48 hours.
KX TECHNOLOGIES: Developing ultra-low loss materials for 5G technologies.
A materials processing company developing advanced feedstock to improve performance of electronic devices in 5G technology applications. KX Technologies’ ultra-low loss materials significantly reduce signal latency and improve transmission distances in high frequency devices to enable breakthroughs in the telecommunications, aerospace, and automotive industries.
L’EAU TECH: An innovative personalized hydrogel based nasal dilator for treating severe nosebleed.
L'Eau Tech, LLC is a start-up medical device research and development company, founded by local emergency physician Andrew Culp in 2018. Our current focus is hydrogel applications for a nasal dilator for enhanced nasal breathing and snoring prevention and a device for septal nosebleed treatment. Provisional patent has been filed for the nosebleed device. We have submitted a Phase I NIH SBIR grant proposal "Development of a Personalized Biocompatible Device to Treat Severe Nosebleeds".
NANORED BIOTECHNOLOGY: We aim to fundamentally change how cancers are treated and to dramatically expand the tools available to doctors and patients.
Nano RED exists to bring the nanotechnology revolution to cancer care. By leveraging a path-breaking platform developed at the National Cancer Institute, we enable precise delivery of therapeutics directly to tumors and the tumor microenvironment. We are developing the next generation of immunotherapies capable of killing cancers and driving durable responses without systemic toxicity.
NANOSUR: Next generation smart pesticides
NanoSUR’s innovative platform enables broad use of RNAi in agriculture, and has developed modified RNA-based products for crop protection. Their proprietary platform produces modified RNA formulations with improved transport properties, resulting in enhanced target delivery and increased efficacy for RNAi.
OVAINNOVTIONS: Reinventing the egg protein business.
OvaInnovations is an innovative business solution disrupting the egg products industry by providing another choice for high-quality, competitively priced product. Key team members have 30 years of experience in developing products with powder eggs and other categories in pet food. Their eggs are organic, free-range, cage-free and meet every demand in the pet food or shrimp feed market.
QUADRAGENICS INC: Advancing BRD4 inhibitors as treatments for asthma, inflammatory bowel disease, and fibrosis.
Discoveries made by QuadraGenics resulted in the synthesis and proof-of-concept for the development of highly selective inhibitors of Bromodomain containing protein 4 (BRD4), key component of innate inflammation responsible for activating and sustaining inflammation.small molecule inhibitors and validated disease target modify the epigenome to combat mucosal inflammation and its downstream fibrotic response.
SYNBIOTIC HEALTH: Leading with Science™ developing ecologically-advanced microbiome ingredients for improved health.
Microbiome science has established the central role of the gut microbial ecosystem in overall health and wellness, yet very few current ingredients have shown any significant impact. Synbiotic Health focuses on understanding and re-modeling this complex gut microbe community, advancing products that meaningfully change the gut microbiota and offer health benefits. Some of the ingredients discovered through our process are the subject of clinical trials and published studies in prestigious journals.
VASCUGEN: Developing regenerative medicines to address vascular diseases.
Vascugen is a regenerative medicine company engaged in the development of advanced medicines and transformative therapies to treat incurable vascular degenerative conditions and injuries. The company has exclusive, worldwide rights to a broad patent portfolio for its platform cellular technology as well as rights covering related products and services for research, diagnostics, therapeutics, tissue engineering, and 3D printing applications.